Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00087620 · ClinicalTrials.gov registry record · Phase 4
A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
A Phase 4 study, sponsored by Hoffmann-La Roche.
- Terminated
- Registry status
- Phase 4
- Development phase
NCT00087620: Clinical Trial Phase 4 study, sponsored by Hoffmann-La Roche.
NCT00087620 is a Phase 4 study that was terminated before completion, run by Hoffmann-La Roche. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00087620, a Phase 4 study, was terminated before completion, sponsored by Hoffmann-La Roche.
- TERMINATED
- Registry status
- Phase 4
- Development phase
Study Summary
To evaluate and compare the time to progression of the combination of capecitabine (825 mg/m2 twice daily) and docetaxel (75mg/m2 i.v.) to that of capecitabine (1000 mg/m2 twice daily) until progressive disease followed sequentially by docetaxel (75 mg/m2 i.v. D1 Q3W).
Interventions
- DRUG XELODA [capecitabine]
Trial Details
| Field | Value |
|---|---|
| Start Date | 2004-09 |
| Est. Completion | 2004-10 |
| Phase | Phase 4 |
Why NCT00087620 stopped before completion
NCT00087620 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which XELODA [capecitabine] is the first listed.
NCT00087620 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00087620 about?
NCT00087620 is a clinical study titled "A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer". To evaluate and compare the time to progression of the combination of capecitabine (825 mg/m2 twice daily) and docetaxel (75mg/m2 i.v.) to that of capecitabine (1000 mg/m2 twice daily) until progressive disease followed sequentially by docetaxel (75 mg/m2 i.v. D1 Q3W).
What is the current status of trial NCT00087620?
This trial is currently terminated. It is a Phase 4 study. The study started on 2004-09. Estimated completion is 2004-10.
What interventions are being tested in trial NCT00087620?
The interventions under investigation include: XELODA [capecitabine] (DRUG).
Who is sponsoring clinical trial NCT00087620?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia